Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Kashiv Biosciences LLC is a private company headquartered in Piscataway, NJ, with subsidiaries in India, that operates as a biopharmaceutical company which offers drug delivery technologies, biosimilars and specialty pharmaceutical products.\nThe company says this about itself: Kashiv Biosciences, LLC is a premier, fully integrated biopharmaceutical company developing advanced-stage biosimilars and specialty biopharmaceutical products. The company is headquartered in Piscataway, NJ with facilities in Chicago, IL and India that all together provide formulation development, analytical testing, biosimilar characterization, and manufacturing of small and large molecules.

Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

Tulane Educational Fund is a private company headquartered in the United States specializing in radio broadcasting stations.

NEUWAY Pharma is committed to bringing transformative neuropharmaceuticals across the blood-brain barrier through its EnPC®, the drug delivery technology based on a natural derived protein capsule. In addition to advancing its proprietary pipeline, the company aims to be a partner of choice in particular for antibody and mRNA drug developers stymied by the hurdles of delivering these and other drug modalities into the brain and CNS tissue. Operating as a drug developer and a delivery expert, NEUWAY will demonstrate the value of its technology through its internal orphan neurological disease pipeline and partnered programs.

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Discovers and develops novel vaccines for the prevention and treatment of bacterial infections

Tianjin Debon Biotechnology Co., Ltd., established on 2010-03-19, Business scope includes biotechnology,Feed Additive Technology,Agricultural Technology,Aquaculture Technology Development,consultation service,transfer,Veterinary drug production,Feed and Feed Additives,pet supplies,fishing tackle,Chemical Products(Hazardous Chemicals,Precursor chemicals excluded),Instrumentation,hardware products,Equipment,Sales of organic fertilizers and microbial fertilizers.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Kashiv Pharma is an emerging pharmaceutical research and drug delivery company focused on developing innovative technologies, improved medicines, and lifecycle management products. Kashiv also offers contract research and development services to pharmaceutical clients in need of formulation and analytical development expertise and/or clinical supply manufacture.

Researches on gen thereapy.

Beijing Huanuo Ogilvy Medical Laboratory Co., Ltd., established on 2015-10-10, The scope of business includes clinical laboratory services;Medicine and Research and Experimental Development.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

IntraBio Ltd. is a British private company located in Begbroke. The firm manufactures drugs for genetic and neurodegenerative diseases.\nThe company says this about itself: IntraBio Inc. is a biopharmaceutical company with a late-stage drug pipeline including novel treatments for common and rare neurodegenerative diseases. IntraBio's platform results from decades of research and investment at premier universities and institutions worldwide. Its clinical programs leverage the expertise in lysosomal function and intracellular calcium signaling of its scientific founders from the University of Oxford and the University of Munich. IntraBio's management team and consultants have vast commercial experience and a successful track record of drug development in the USA and Europe. Together, IntraBio's team translates innovative scientific research in the fields of lysosomal biology, autophagy, and neurology into novel drugs for a broad spectrum of genetic and neurodegenerative diseases so to significantly improve the lives of patients and their families. IntraBio Inc. is a US corporation with its principal laboratories and offices in Oxford, United Kingdom.

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.